Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, A Microbiota-Based Drug for the Prevention of Recurrent Clostridium Difficile Infection: Results from Punch CD 2, A Randomized Doubleblind Placebo-Controlled Trial